FindTrial
Sign In

Prevalence and Risk Factors for Pain and Related Adverse Reactions Among Breast Cancer Survivors on Aromatase Inhibitors

Doctor of Medical Sciences

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05628077
Enrollment
1200
Registered
2022-11-28
Start date
2022-12-30
Completion date
2023-04-20
Last updated
2023-03-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anxiety, Aromatase Inhibitors, Breast Cancer, Depression, Endocrine Therapy, Pain, Sleep

Brief summary

We obtained the occurrence of pain sensation, pain mood, sleep, etc. during endocrine therapy in breast cancer patients through telephone follow-up, and analyzed risk factors through artificial intelligence

Interventions

OTHERNo intervention

No intervention

Sponsors

Peking University People's Hospital
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 90 Years
Healthy volunteers
No

Inclusion criteria

\- Breast cancer survivors on aromatase inhibitors

Exclusion criteria

* Advanced breast cancer

Design outcomes

Primary

MeasureTime frame
Prevalence and risk factors for pain and related adverse reactions among breast cancer survivors on aromatase inhibitors2022-10 ---2023-03

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026